Joseph Christenbury, MD
Cornea and External Diseases Specialist · Atlanta, GANPI 1679816458
Payments from drug & device makers
Across 335 payments — averaging $780.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$105K
- Dompe Farmaceutici S.p.a.$82K
- Novartis$36K
- Biotissue Holdings Inc.$14K
- Glaukos Corporation$11K
- Dompe US, Inc.$5K
- plus $8K from 27 others
What the payments were for
- Consulting fees$12,30040%
- Speaking & faculty fees$4,83916%
- Travel & lodging$2,5168%
- Food & beverage$11,31436%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 3 | $105,234 |
| Dompe Farmaceutici S.p.a. | 12 | $82,042 |
| Novartis | 32 | $36,027 |
| Biotissue Holdings Inc. | 23 | $13,972 |
| Glaukos Corporation | 52 | $10,748 |
| Dompe US, Inc. | 18 | $5,088 |
| Johnson & Johnson Surgical Vision, Inc. | 19 | $2,483 |
| Alcon | 31 | $1,662 |
| AbbVie(2 entities) | 22 | $618 |
| Sun Pharmaceutical Industries Inc. | 28 | $587 |
| Oyster Point Pharma, Inc. | 13 | $455 |
| Rxsight Inc | 7 | $389 |
| Bausch & Lomb Americas Inc. | 17 | $300 |
| Mallinckrodt Hospital Products Inc. | 9 | $297 |
| Carl Zeiss Meditec USA, Inc. | 3 | $267 |
| Sight Sciences, Inc. | 9 | $245 |
| Harrow Eye, LLC | 7 | $191 |
| Carl Zeiss Meditec, Inc. | 2 | $189 |
| Mallinckrodt Enterprises LLC | 3 | $155 |
| Thea Pharma Inc. | 1 | $115 |
| Kala Pharmaceuticals, Inc. | 6 | $105 |
| Tarsus Pharmaceuticals, Inc. | 3 | $85 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $79 |
| Heidelberg Engineering, Inc. | 1 | $32 |
| Baxter Healthcare | 1 | $24 |
| Eyevance Pharmaceuticals LLC | 2 | $24 |
| Lensar, Inc. | 1 | $23 |
| Eyepoint US, Inc. | 1 | $21 |
| Ivantis, Inc | 1 | $16 |
| Lumenis, Inc | 1 | $15 |
| Ocular Therapeutix, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Iridex Corporation | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$6,800
- AmnioGraft$6,800
- AmnioGuard$2,000
- Tecnis 1-piece IOL$1,887
- Tecnis 3-piece IOL$1,887
- Tecnis Symphony IOL$1,887
- Tecnis Symphony Toric IOL$1,887
- Photrexa Viscous and Photrexa$595
- KXL System$513
- Clareon$502
- Photrexa$475
- Oxervate$336
- QUATERA 700$294
- PanOptix$258
- TYRVAYA$255
- ARTEVO 800$146
- IOLMaster 700$146
- VERACITY SURGICAL$146
- IACCESS$138
- CE-marked KXLA system$131
How this compares
Too few cornea and external diseases specialist providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 16 | $903,934 |
| RestasisCyclosporine | 130 | $115,417 |
| XiidraLifitegrast | 44 | $45,522 |
| Cyclosporine | 63 | $45,262 |
| MieboPerfluorohexyloctane/Pf | 27 | $24,058 |
| TyrvayaVarenicline Tartrate | 25 | $23,891 |
| Prednisolone Acetate | 724 | $23,847 |
| LumiganBimatoprost | 31 | $16,198 |
| CequaCyclosporine | 16 | $14,446 |
| MoxifloxacinMoxifloxacin Hcl | 558 | $11,716 |
| Fluorometholone | 125 | $11,468 |
| CombiganBrimonidine Tartrate/Timolol | 29 | $7,787 |
| Brimonidine Tartrate | 73 | $6,539 |
| ValacyclovirValacyclovir Hcl | 131 | $6,114 |
| Alphagan PBrimonidine Tartrate | 16 | $5,684 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $5,088 | $903,93416 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $618 | $145,085206 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $300 | $69,58071 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $455 | $23,89125 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $587 | $14,44616 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa | $79 | $9,69035 claims |
| AlconSimbrinza | $1,662 | $4,35519 claims |
| Eyevance Pharmaceuticals LLCFlarex | $24 | $1,47712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Atlanta
- William LeeAtlanta$545K
- Soroosh BehshadAtlanta$7K
- Evan LoftAtlanta$2K
- Amit BajajAtlanta$1K
- Colton McCoyAtlanta$553
- Amy EstesAugusta$2K
- Abigail KalishMarietta$1K
- Barbara SmithMarietta$633
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.